Harbin Yuheng Pharmaceutical

Harbin Yuheng Pharmaceutical is a major Chinese pharmaceutical company specializing in the research, development, manufacturing, and commercialization of a broad spectrum of healthcare products. The company maintains a diverse portfolio that includes chemical drugs, modern traditional Chinese medicine, and innovative biologics, with a strong focus on oncology, cardiovascular, and orthopedic therapeutic areas. A significant milestone for the company is the development of the PD-1 inhibitor zimberelimab, which was advanced through its subsidiary Gloria Biosciences in collaboration with WuXi Biologics. Harbin Yuheng operates multiple GMP-certified production facilities across China and is listed on the Shenzhen Stock Exchange. The company continues to transition from a generic-led business model toward a more innovation-driven pipeline through strategic partnerships and internal R&D.